Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 May 20;34(15):1723-31.
doi: 10.1200/JCO.2015.66.1181. Epub 2016 Feb 22.

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Guy A van Hazel  1 , Volker Heinemann  2 , Navesh K Sharma  2 , Michael P N Findlay  2 , Jens Ricke  2 , Marc Peeters  2 , David Perez  2 , Bridget A Robinson  2 , Andrew H Strickland  2 , Tom Ferguson  2 , Javier Rodríguez  2 , Hendrik Kröning  2 , Ido Wolf  2 , Vinod Ganju  2 , Euan Walpole  2 , Eveline Boucher  2 , Thomas Tichler  2 , Einat Shacham-Shmueli  2 , Alex Powell  2 , Paul Eliadis  2 , Richard Isaacs  2 , David Price  2 , Fred Moeslein  2 , Julien Taieb  2 , Geoff Bower  2 , Val Gebski  2 , Mark Van Buskirk  2 , David N Cade  2 , Kenneth Thurston  2 , Peter Gibbs  2
Affiliations
Clinical Trial

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Guy A van Hazel et al. J Clin Oncol. .

Erratum in

  • ERRATA.
    [No authors listed] [No authors listed] J Clin Oncol. 2016 Nov 20;34(33):4059. doi: 10.1200/JCO.2016.70.8982. J Clin Oncol. 2016. PMID: 29236595 No abstract available.

Abstract

Purpose: SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untreated metastatic colorectal cancer.

Patients and methods: Chemotherapy-naïve patients with liver metastases plus or minus limited extrahepatic metastases were randomly assigned to receive either modified FOLFOX (mFOLFOX6; control) or mFOLFOX6 plus SIRT (SIRT) plus or minus bevacizumab. The primary end point was progression-free survival (PFS) at any site as assessed by independent centralized radiology review blinded to study arm.

Results: Between October 2006 and April 2013, 530 patients were randomly assigned to treatment (control, 263; SIRT, 267). Median PFS at any site was 10.2 v 10.7 months in control versus SIRT (hazard ratio, 0.93; 95% CI, 0.77 to 1.12; P = .43). Median PFS in the liver by competing risk analysis was 12.6 v 20.5 months in control versus SIRT (hazard ratio, 0.69; 95% CI, 0.55 to 0.90; P = .002). Objective response rates (ORRs) at any site were similar (68.1% v 76.4% in control v SIRT; P = .113). ORR in the liver was improved with the addition of SIRT (68.8% v 78.7% in control v SIRT; P = .042). Grade ≥ 3 adverse events, including recognized SIRT-related effects, were reported in 73.4% and 85.4% of patients in control versus SIRT.

Conclusion: The addition of SIRT to FOLFOX-based first-line chemotherapy in patients with liver-dominant or liver-only metastatic colorectal cancer did not improve PFS at any site but significantly delayed disease progression in the liver. The safety profile was as expected and was consistent with previous studies.

Trial registration: ClinicalTrials.gov NCT00724503.

PubMed Disclaimer

Comment in

Publication types

MeSH terms

Supplementary concepts

Associated data